Globeflex Capital L P Acquires 60,656 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Globeflex Capital L P increased its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 217.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 88,596 shares of the company's stock after acquiring an additional 60,656 shares during the quarter. Globeflex Capital L P owned about 0.12% of Kiniksa Pharmaceuticals worth $1,752,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of KNSA. China Universal Asset Management Co. Ltd. increased its stake in shares of Kiniksa Pharmaceuticals by 12.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock worth $174,000 after purchasing an additional 1,004 shares during the period. Franklin Resources Inc. increased its position in Kiniksa Pharmaceuticals by 1.7% in the 3rd quarter. Franklin Resources Inc. now owns 67,533 shares of the company's stock worth $1,798,000 after buying an additional 1,100 shares during the period. New York State Common Retirement Fund lifted its holdings in shares of Kiniksa Pharmaceuticals by 12.4% during the fourth quarter. New York State Common Retirement Fund now owns 15,248 shares of the company's stock worth $302,000 after buying an additional 1,680 shares during the last quarter. Quarry LP bought a new stake in shares of Kiniksa Pharmaceuticals in the third quarter valued at approximately $50,000. Finally, Martingale Asset Management L P increased its position in Kiniksa Pharmaceuticals by 6.8% during the third quarter. Martingale Asset Management L P now owns 48,460 shares of the company's stock worth $1,211,000 after acquiring an additional 3,083 shares during the period. Institutional investors and hedge funds own 53.95% of the company's stock.

Remove Ads

Kiniksa Pharmaceuticals Stock Performance

Shares of KNSA stock traded up $0.47 during mid-day trading on Wednesday, reaching $23.08. The company's stock had a trading volume of 396,095 shares, compared to its average volume of 405,125. The firm's 50-day moving average is $20.10 and its two-hundred day moving average is $22.07. The company has a market cap of $1.68 billion, a P/E ratio of -164.85 and a beta of 0.48. Kiniksa Pharmaceuticals, Ltd. has a 1-year low of $16.56 and a 1-year high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company had revenue of $122.50 million for the quarter, compared to analyst estimates of $123.42 million. During the same period in the previous year, the firm posted $0.35 earnings per share. The firm's revenue for the quarter was up 46.9% compared to the same quarter last year. Sell-side analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Insider Activity at Kiniksa Pharmaceuticals

In other news, CFO Mark Ragosa sold 36,372 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $22.25, for a total transaction of $809,277.00. Following the completion of the sale, the chief financial officer now owns 22,958 shares of the company's stock, valued at approximately $510,815.50. This trade represents a 61.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Eben Tessari sold 14,000 shares of the business's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $19.57, for a total value of $273,980.00. Following the completion of the transaction, the chief operating officer now directly owns 81,975 shares in the company, valued at $1,604,250.75. The trade was a 14.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 73,423 shares of company stock valued at $1,541,812 in the last 90 days. 54.57% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently commented on KNSA. Wedbush reiterated an "outperform" rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They issued a "buy" rating and a $40.00 target price for the company. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $37.17.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.